Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

MIRACLE Integrated multi-angle research and training network to eradicate leukemia minimal residual disease

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 December 2024 to 30 November 2028
Status
Running
EU funding
€2.6m
Total cost
—
Partners
22 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101167512

What the project is doing

In the project's own words, from its summary on CORDIS.

An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemia (AML), which is generally a disease of the elderly, while acute lymphoid leukemia (ALL) is most prevalent in children. The biggest problem associated with leukemia treatment is persistence of residual therapy-resistant cancer cells, called minimal residual disease (MRD). MRD can latently persist in the patient for many months, and in response to unknown signals can reawaken and initiate a relapse, which is difficult to treat and responsible for the low survival rates of patients.

Currently, knowledge on mechanisms responsible for persistence of MRD and initiation of leukemia relapse is lacking, making development of therapeutics eradicating MRD difficult and hampering improvement of patient cure rates. MIRACLE aims at eradication of MRD and development of clinically efficient treatment strategies that can deliver long-lasting benefit to patients by training a new generation of researchers. MIRACLE will elucidate the leukemia MRD landscape by integrating the knowledge on mechanisms driving persistence of MRD from different angles, and by the subsequent design of efficient and less toxic, novel targeted combination therapy with increased capacity to induce deep responses in patients.

With its multidisciplinary team of scientists from academia and industry MIRACLE aims to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to MRD, and to progress effective treatments to the clinic. The researchers within MIRACLE will be trained to obtain a unique combination of skills in innovative high-tech technologies, advanced data analysis tools and artificial intelligence, organ-on-chip MRD models, and drug and immunotherapy testing, and will come with innovative ideas to advance future leukemia treatment by integration of several disciplines and data sources.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Active MotifWaterlooBelgiumAssociatedpartner
Katholieke Universiteit LeuvenLeuvenBelgiumAssociatedpartner
Somersault18:24DiestBelgiumAssociatedpartner
Vib VzwZwijnaarde - GentBelgiumParticipant
Univerzita KarlovaPraha 1CzechiaParticipant
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Klinikum Der Johann Wolfgang Von Goethe UniversitaetFrankfurt Am MainGermanyAssociatedpartner
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Institute of Biomedical Research of Salamanca (IBSAL)SoriaSpainAssociatedpartner
Universidad De SevillaSevillaSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
Universita Vita-Salute San RaffaeleMilanoItalyAssociatedpartner
Brain & Body CompanyAmsterdamNetherlandsAssociatedpartner
Fundament SubsidieadviesHilversumNetherlandsAssociatedpartner
Mimetas BVLeidenNetherlandsParticipant
Ortec Optimization Technology BVZoetermeerNetherlandsAssociatedpartner
Stichting Proefdiervrij* Dutch Society for the Replacement of Animal TestingDen HaagNetherlandsAssociatedpartner
Stichting VuAmsterdamNetherlandsAssociatedpartner
Stichting HematonUtrechtNetherlandsAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI